Oral Drug Delivery Videos

  1. Next Generation Drug And Biologics Delivery Technologies 5/23/2025

    In this segment of the Drug Delivery Leader Live online event, Innovations In Drug Delivery: Opportunities For Enhancing Familiar, Mature Approaches, host Fran DeGrazio asks panelists James Wabby of biopharmaceutical company AbbVie and Carolyn Dorgan and Courtney Evans of device consultancy Suttons Creek to comment on trends and advances they anticipate in the next phase of delivery development. Those include combination therapies, nanotechnology, reconstitution, and microfluidics.

  2. Minitabs Technology 8/29/2024

    Discover a multiparticulate system that provides unparalleled flexibility in dosage forms, which allows you to create customized release profiles, precise dosing, and a wide range of delivery options.

  3. The Fusion-Based, Solvent-Free Process Disrupting Spray Drying 3/19/2024

    Review a commercially-ready process capable of reproducing spray-dried dispersions with less manufacturing complexity and environmental impact, and out-designing and outperforming spray drying.

  4. Global Harmonization Of Combination Products Regulatory 1/12/2026

    In this segment of the Drug Delivery Leader Live online event, Eying The Drug Delivery Regulatory Landscape: The 'Must See' Watch List For 2026, Chief Editor Tom von Gunden asks the panel to comment on regulatory movements of note. From his combination products and global operations leadership roles at FDA and now as regulatory consultant, panelist Barr Weiner points to global harmonization of regulatory definitions and requirements. Panelists Rumi Young and Fran DeGrazio weigh in on stability testing and specific ICH, ISO, and AAMI standards.

  5. What's In A Combination Product Development Lifecycle? 10/8/2025

    In this segment of the Drug Delivery Leader Live online event, Next-Gen Drug Delivery: Rethinking Routes For New Therapies, Carolyn Dorgan, director of technical services at device design consultancy Suttons Creek, lays out the phases and key activities in the development of a combination product or combination therapy. She underscores the importance of integrated development when merging medicinal product development with delivery device development. 

  6. Future Of Pharma Packaging: Trends, Tech, And Patient Solutions 9/25/2025

    Explore how traditional and innovative pharmaceutical packaging formats improve patient adherence, support emerging therapies, and shape the future of drug delivery and treatment outcomes.

  7. Preferences And Challenges In Oral Drug Delivery 6/12/2026

    In this segment of the Drug Delivery Leader Live online event, Advanced Oral Delivery: Maximizing Molecules, Targets, And Adherence, Chief Editor Tom von Gunden asks panelist Eduardo Jule to provide a foundational overview of the current state of reliance on oral delivery. Jule points to patient preference for oral delivery while acknowledging challenges and limitations in the approach. 

  8. Management Responsibility and the New QMSR 7/11/2024

    What is management’s responsibility in the implementation of approaches to the new QMSR? In this segment of the Drug Delivery Leader Live event New FDA QMSR: Its Role in Part 4 Compliance for Combination Products, consultant Laurie Auerbach of Compliance Prodigies underscores the criticality of management commitment to and engagement in the process.

  9. What Happened to CAPA (Corrective and Preventive Actions) Requirements? 7/11/2024

    Is CAPA still part of the requirements picture for the new QMSR? In this segment of the Drug Delivery Leader Live event New FDA QMSR: Its Role in Part 4 Compliance for Combination Products, consultant Ed Bills of Edwin Bills Consultant discusses changes in the treatment of corrective and preventive actions.

  10. Halting HAE Attacks Via Oral Delivery With Pharvaris' Wim Souverijns And Stefan Abele 3/20/2025

    In this episode of Sit and Deliver, host Tom von Gunden talks with Chief Commercial Officer Wim Souverijns and Chief Technical Operations Officer Stefan Abele from Pharvaris, a developer of orally administered treatments for hereditary angioedema, or HAE.